BridgeBio Oncology Therapeutics (BBOT) investor relations material

Company evolution and financing

• Spun out as a private company in May 2024, raising $200 million to advance in-house discovered oncology programs.

• Rapidly initiated three clinical programs between June 2024 and March 2025.

• Completed a de-SPAC transaction with Helix Acquisition Corp. II, raising $380 million with minimal redemptions.

• Now publicly traded on NASDAQ, securing a strong financial runway for clinical development.

• Holds $418 million in cash as of Q2 2025, supporting operations into 2028 and preregistrational studies.

Strategic vision and portfolio focus

• Aims to achieve proof of concept for three clinical assets, enabling data-driven decisions for future development.

• Focuses on innovative small molecule approaches targeting KRAS and PI3Kα, two of the most mutated oncogenes in cancer.

• Emphasizes the potential of both individual assets and their combinations to address unmet needs in oncology.

• Sees significant opportunity in lung, pancreas, colon, and breast cancers.

• Plans to leverage portfolio synergies, especially in KRAS mutant cancers.

Drug design and differentiation

• Utilizes advanced medicinal chemistry and structural biology to develop inhibitors targeting both on- and off-states of KRAS.

• BBO-8520, a KRAS G12C inhibitor, directly binds the SWITCH2 pocket, achieving efficacy with low drug exposure and a favorable safety profile.

• Early clinical data show a 60% confirmed response rate and no grade 3 or liver toxicities.

• Breaker program (BBO-10203) inhibits RAS-PI3Kα interaction, avoiding hyperglycemia and expanding the eligible patient population.

• Pan-KRAS inhibitor (BBO-11818) selectively targets G12X mutations, sparing H and N isoforms, with first data expected in H2 2026.